Robert Driscoll
Stock Analyst at Wedbush
(3.61)
# 859
Out of 4,479 analysts
119
Total ratings
33.75%
Success rate
10.73%
Average return
Main Sectors:
Top Industries:
25 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GERN Geron | Reiterates: Outperform | $7 | $4.34 | +61.29% | 8 | Jun 7, 2024 | |
| TNGX Tango Therapeutics | Maintains: Outperform | $18 → $11 | $9.00 | +22.22% | 3 | May 23, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Outperform | $11 | $3.94 | +179.19% | 2 | May 22, 2024 | |
| CGEM Cullinan Oncology | Reiterates: Outperform | $36 | $16.73 | +115.18% | 2 | May 16, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $17.28 | +62.04% | 5 | May 10, 2024 | |
| CTMX CytomX Therapeutics | Upgrades: Outperform | $3 → $8 | $1.33 | +501.50% | 8 | May 9, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Outperform | $30 | $15.30 | +96.08% | 5 | May 9, 2024 | |
| IGMS IGM Biosciences | Reiterates: Outperform | $20 | $6.79 | +194.55% | 7 | May 9, 2024 | |
| RVMD Revolution Medicines | Maintains: Outperform | $42 → $46 | $38.81 | +18.53% | 1 | May 9, 2024 | |
| JANX Janux Therapeutics | Maintains: Outperform | $53 → $74 | $41.72 | +77.37% | 6 | May 8, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $52 | $25.98 | +100.15% | 5 | May 8, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $35.92 | +44.77% | 6 | May 8, 2024 | |
| KURA Kura Oncology | Reiterates: Outperform | $37 | $21.20 | +74.53% | 5 | May 3, 2024 | |
| ELEV Elevation Oncology | Reiterates: Outperform | $8 | $2.86 | +179.72% | 7 | May 3, 2024 | |
| ACET Adicet Bio | Reiterates: Outperform | $5 | $1.15 | +334.78% | 7 | Apr 23, 2024 | |
| FHTX Foghorn Therapeutics | Reiterates: Outperform | $13 | $5.84 | +122.60% | 6 | Apr 10, 2024 | |
| BDTX Black Diamond Therapeutics | Maintains: Outperform | $10 → $16 | $4.70 | +240.43% | 7 | Apr 8, 2024 | |
| APRE Aprea Therapeutics | Maintains: Outperform | $9 → $11 | $4.03 | +172.95% | 2 | Mar 27, 2024 | |
| CMPX Compass Therapeutics | Reiterates: Outperform | $8 | $0.95 | +746.11% | 2 | Mar 22, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Neutral | $12 → $15 | $4.19 | +258.00% | 8 | Feb 28, 2024 | |
| OMGA Omega Therapeutics | Reiterates: Outperform | $12 | $2.25 | +433.33% | 3 | Jan 4, 2024 | |
| REPL Replimune Group | Reiterates: Outperform | $52 | $9.36 | +455.56% | 4 | Nov 8, 2023 | |
| DAWN Day One Biopharmaceuticals | Maintains: Outperform | $39 → $35 | $13.58 | +157.73% | 5 | Nov 7, 2023 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $9 | $2.35 | +282.98% | 1 | Aug 24, 2023 | |
| ABUS Arbutus Biopharma | Upgrades: Outperform | n/a | $3.12 | - | 4 | May 19, 2020 |
Geron
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $4.34
Upside: +61.29%
Tango Therapeutics
May 23, 2024
Maintains: Outperform
Price Target: $18 → $11
Current: $9.00
Upside: +22.22%
Monte Rosa Therapeutics
May 22, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.94
Upside: +179.19%
Cullinan Oncology
May 16, 2024
Reiterates: Outperform
Price Target: $36
Current: $16.73
Upside: +115.18%
Tyra Biosciences
May 10, 2024
Reiterates: Outperform
Price Target: $28
Current: $17.28
Upside: +62.04%
CytomX Therapeutics
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $1.33
Upside: +501.50%
Arcus Biosciences
May 9, 2024
Reiterates: Outperform
Price Target: $30
Current: $15.30
Upside: +96.08%
IGM Biosciences
May 9, 2024
Reiterates: Outperform
Price Target: $20
Current: $6.79
Upside: +194.55%
Revolution Medicines
May 9, 2024
Maintains: Outperform
Price Target: $42 → $46
Current: $38.81
Upside: +18.53%
Janux Therapeutics
May 8, 2024
Maintains: Outperform
Price Target: $53 → $74
Current: $41.72
Upside: +77.37%
Arvinas
May 8, 2024
Reiterates: Outperform
Price Target: $52
Current: $25.98
Upside: +100.15%
IDEAYA Biosciences
May 8, 2024
Reiterates: Outperform
Price Target: $52
Current: $35.92
Upside: +44.77%
Kura Oncology
May 3, 2024
Reiterates: Outperform
Price Target: $37
Current: $21.20
Upside: +74.53%
Elevation Oncology
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.86
Upside: +179.72%
Adicet Bio
Apr 23, 2024
Reiterates: Outperform
Price Target: $5
Current: $1.15
Upside: +334.78%
Foghorn Therapeutics
Apr 10, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.84
Upside: +122.60%
Black Diamond Therapeutics
Apr 8, 2024
Maintains: Outperform
Price Target: $10 → $16
Current: $4.70
Upside: +240.43%
Aprea Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $9 → $11
Current: $4.03
Upside: +172.95%
Compass Therapeutics
Mar 22, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.95
Upside: +746.11%
Zentalis Pharmaceuticals
Feb 28, 2024
Maintains: Neutral
Price Target: $12 → $15
Current: $4.19
Upside: +258.00%
Omega Therapeutics
Jan 4, 2024
Reiterates: Outperform
Price Target: $12
Current: $2.25
Upside: +433.33%
Replimune Group
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $9.36
Upside: +455.56%
Day One Biopharmaceuticals
Nov 7, 2023
Maintains: Outperform
Price Target: $39 → $35
Current: $13.58
Upside: +157.73%
Werewolf Therapeutics
Aug 24, 2023
Initiates: Outperform
Price Target: $9
Current: $2.35
Upside: +282.98%
Arbutus Biopharma
May 19, 2020
Upgrades: Outperform
Price Target: n/a
Current: $3.12
Upside: -